David Sinclair’s secret pill is the decoy. His longevity contest is really a bid to privatize the measurement of aging itself — and a Saudi sovereign wealth fund is paying to host the carving of the ruler.
The pill is a decoy. The most valuable thing in David Sinclair’s longevity contest is not a drug that makes you ten years younger; it is the right to decide what “ten years younger” means — and a Saudi sovereign wealth fund has put a hundred and one million dollars on the table to host the auction. Sinclair won’t say what’s in his candidate, code-named SL-100; he calls its contents highly confidential and his animal data sits unpublished in a Harvard freezer. None of that secrecy is a problem for the contest, because the contest does not actually need his pill to work. It needs a tape measure, and it needs that tape measure to belong to someone.
However the people running the XPrize Healthspan competition have told you exactly this, in the open, and the field has politely declined to hear it. Pressed on what the contest is for, its executive director says the primary purpose is to solve the measurement problem — to invent the standardized way of scoring how a person ages. Sit with the structure that admission requires. You cannot run a contest scored on a metric that does not yet exist without building the metric as you go. And the people building it are the contestants. Sixty-five teams competing for the prize are simultaneously authoring the exam that decides who wins. The contest is not a race judged against a ruler; it is a room full of competitors carving one.
No conspiracy is required for this, and assuming one is the error that lets it keep working. Nobody has to meet in a back room. The incentive points in a single direction — toward a metric that flatters the kind of intervention already in the building — and a hundred and one million dollars is enough to make everyone drift that way without a word exchanged. Right now a dozen biological clocks compete and not one is blessed by a regulator; that vacancy is not a problem the contest is nobly solving so much as the opening it was built to fill. Every standard war starts plural. It ends with whoever had the adoption, the capital, and the forcing event. The contest is the forcing event.
Look at what the secrecy is doing, because it is not doing what secrecy usually does. In ordinary drug development you hide a compound because disclosure would let a rival copy a hard-won, fragile result. Here the field mostly agrees the underlying problem is solvable — Sinclair’s own rival, the Harvard biologist whose mice the chemicals poisoned, concedes that improving the combinations makes sense. If the toxicity is a dosing puzzle rather than a wall, then there is no fragile result to protect; there is only a recipe. And a recipe everyone could in principle find becomes valuable only when exactly one party knows the knot and the rest are kept out. Sinclair’s confidentiality is not protecting a discovery. It is converting a public problem into private property, and keeping it private just long enough to set the standard that the property will later be sold against. Sinclair does not even have to win. The contest needs a number that moves, not his molecule in particular; any team’s signal, genuine or merely noisy, is enough to certify the ruler the whole field will then be measured against. The drug does not have to be real. It has to stay secret on schedule.
Meanwhile the actual human experiment is already running, dressed as something else. While SL-100 stays locked up, a separate operation working for Sinclair’s team is already dosing people with an oral reprogramming cocktail — and, by its operator’s own account, calls these clinical trials. The published version of such a cocktail, the recipe Sinclair once filed a patent on, runs on a supplement, an old antidepressant, and an experimental molecule once tested against Alzheimer’s: each an ingredient a doctor may legally prescribe to one patient at a time, for any reason, including the unusual objective of turning back a clock. Bundle those legal parts into a protocol and you have a clinical trial. Hand them out one prescription at a time and you have a thousand individual acts of medicine that no regulator ever reviews as a trial. The compound that would need FDA approval is the one nobody can see. The one already inside human beings needs no approval at all, by construction. That is not a loophole the contest stumbled into. It is the load-bearing wall.
The contest’s structure also explains a silence that should be louder. Vadim Gladyshev — a Harvard biologist on a rival team — ran the honest version: pumps implanted in mice, seven compounds released on a schedule. He reported the obvious, inconvenient result: at low doses nothing happened, at high doses the animals were poisoned. That is the classic signature of a therapeutic window that may not exist. It is also the single most useful data point any of these teams has produced, and the prize structure punishes the man who produced it. A negative result published on time is a competitive liability; a positive result kept unpublished is a strategic asset. A contest that rewards secrecy and penalizes disclosure does not select for the drug most likely to be safe. It selects for the team most willing to withhold the data that would tell you.
None of this would survive a week of scrutiny if scrutiny were the currency. It isn’t; affiliation is. In 2024 Sinclair resigned a longevity society’s presidency after claiming a supplement had reversed aging in dogs — a claim one scientist flatly called a lie. He kept the Harvard appointment, kept the books, kept the social-media following, and kept his slot in a hundred-million-dollar contest. The mechanism here is not personal credulity; it is institutional. A “reversed-aging” claim that would be laughed out of the room from an unaffiliated lab survives, even profits, when it carries a Harvard return address. In a field with no agreed measurement, the prestige is the measurement — until the contest manufactures the real one, at which point the prestige will have helped decide whose protocol becomes the standard.
This is where the Saudi money stops being a reputational footnote and becomes the whole point. The boring reading of Hevolution’s check is image-laundering: petrostate buys nice headlines, like a golf tour or a soccer club. The sharper reading is that this is the cheapest sovereign position on the board — and it needs no master plan in Riyadh to pay off. Aging is the one disease every human being eventually contracts. Whoever ends up holding the instrument that certifies its reversal holds a chokepoint on the largest market that will ever exist, and for the price of a mid-tier transfer fee the fund underwriting the contest has bought a seat at the moment that instrument is born, ratified by sixty-five teams and dressed in Harvard letterhead before any government agency convenes a meeting. The agency, when it finally does convene, inherits a finished standard with industry buy-in, published results, and media legitimacy already attached. The contest’s director stood in front of FDA officials and asked, on the field’s behalf, how anyone would know if a longevity drug worked. It was framed as humility. It was a notice of intent. The answer to that question is being written right now, by the people who will sell the thing the answer measures.
So the stakes are not really about one secret pill or one Harvard reputation. The stakes are about who gets to forge the instruments by which a market certifies its own product — and the template being prototyped here is the ratings-agency model imported into biology: design the test you sit, pay the body that grades you, hand the regulator a fait accompli and call it innovation.
The reassuring rebuttal is that nobody can really own a metric — that aging measurement will stay plural and contested, more like credit scoring than a single agency’s stamp. Look harder at that comparison. FICO does not own the concept of creditworthiness either, and it has never needed to. It became the default; its formula is proprietary and unpublished; no one ever voted for it; and it now silently gates housing, employment, and the price of money for everyone who lives inside it. A privately held, uninspectable number that the whole system defers to is not the gentle version of this story. It is the finished version. That is the future the contest is auditioning for, and noting that several clocks still compete only describes the round before consolidation.
If this works once, every therapeutic class with enough capital behind it learns the same trick: don’t lobby to weaken the standard, just be the standard before the regulator wakes up. The subjects swallowing off-label cocktails this year are the visible casualties. The invisible one is everyone who will later be sold ten younger years, measured against a yardstick that the sellers carved, funded by a kingdom, and stamped with a university’s name.
There is one document that would put all of this to rest. Publish the terms under which the winning measurement becomes available to everyone else — make the standard open, unlicensed, owned by no competitor and no funder — and the argument in this essay collapses on the spot. The XPrize and its Saudi backer have commissioned a ruler worth more than the prize itself, and will not say who is to hold it. One locked box holds the compound; the second holds the standard — and the second is the one that matters.
They keep asking, very earnestly, how we would know if it worked. The contest exists to make sure that by the time anyone can answer, the people selling the answer already own the question.
Note: This essay is my opinionated response to Antonio Regalado, “David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition,” MIT Technology Review, June 9, 2026.
cafebedouin.org 